Neurostimulation + Therapy for Emotional Regulation Issues
Trial Summary
What is the purpose of this trial?
This trial tests a new method that combines teaching emotion management skills with a type of brain stimulation. The goal is to help adults who struggle to calm down when upset and have certain mental health conditions. The brain stimulation aims to make it easier for them to learn and use these skills effectively.
Will I have to stop taking my current medications?
You will not have to stop taking your current medications, but you must keep the dose the same throughout the study if you are stable on them for the past 4 weeks. Changes are only allowed in case of a medical emergency.
What data supports the effectiveness of the treatment Neurostimulation + Therapy for Emotional Regulation Issues?
Research shows that repetitive transcranial magnetic stimulation (rTMS) can influence brain areas involved in emotion regulation, potentially helping with emotional issues. Studies have found that rTMS can have mood-elevating effects, especially in conditions like depression, suggesting it might be beneficial for emotional regulation.12345
Is repetitive transcranial magnetic stimulation (rTMS) generally safe for humans?
How does the treatment Neurostimulation + Therapy for Emotional Regulation Issues differ from other treatments for emotional regulation issues?
This treatment combines repetitive transcranial magnetic stimulation (rTMS), which uses magnetic fields to stimulate nerve cells in the brain, with emotional awareness training to improve emotional regulation. Unlike other treatments that may focus solely on medication or therapy, this approach uniquely integrates brain stimulation with skills training to target both the neurological and behavioral aspects of emotional dysregulation.1112131415
Research Team
Andrada D Neacsiu, PhD
Principal Investigator
Duke University
Eligibility Criteria
This trial is for adults aged 18-55 who struggle with emotional regulation and have been diagnosed with certain mood, anxiety, stress-related, impulse control, ADHD or eating disorders. They must score high on the Emotion Regulation Scale and agree to keep their psychotherapy and medication doses consistent throughout the study. People are excluded if they have severe psychiatric conditions like bipolar I disorder or psychosis, substance abuse issues, a low verbal IQ, serious medical illnesses that could interfere with neurostimulation or MRI scans.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a one-session training combining emotion regulation skills with excitatory neurostimulation over the dorsolateral prefrontal cortex (dlPFC).
Follow-up
Participants undergo a follow-up neuroimaging scan and bio-behavioral assessments to evaluate neural and behavioral changes.
Long-term Follow-up
Participants complete an exit interview and additional bio-behavioral assessments to evaluate long-term effects.
Treatment Details
Interventions
- Active Repetitive Transcranial Magnetic Stimulation (rTMS) (Neurostimulation)
- Cognitive Restructuring (Behavioral Intervention)
- Electrical Scalp Stimulation (Neurostimulation)
- Emotional Awareness Training (Behavioral Intervention)
- Sham Repetitive Transcranial Magnetic Stimulation (rTMS) (Neurostimulation)
Active Repetitive Transcranial Magnetic Stimulation (rTMS) is already approved in Canada for the following indications:
- Major Depressive Disorder
- Obsessive-Compulsive Disorder
Find a Clinic Near You
Who Is Running the Clinical Trial?
Duke University
Lead Sponsor
Mary E. Klotman
Duke University
Chief Executive Officer since 2017
MD from Duke University School of Medicine
Michelle McMurry-Heath
Duke University
Chief Medical Officer since 2020
MD from Duke University School of Medicine
National Institute of Mental Health (NIMH)
Collaborator
Dr. Joshua A. Gordon
National Institute of Mental Health (NIMH)
Chief Executive Officer since 2016
MD, PhD
Dr. Shelli Avenevoli
National Institute of Mental Health (NIMH)
Chief Medical Officer
PhD